Skip to main content
. 2014 Jun 10;2014:423181. doi: 10.1155/2014/423181

Figure 3.

Figure 3

Longitudinal analysis of peripheral blood CD8+CD28+ and CD8+CD28 T cells (a) and CD8+CD28+/CD8+CD28 T cells ratio (b) in 48 CHB patients over a 52-week course of Peg-IFN-α therapy. *P < 0.05, **P < 0.01, for the difference in the peripheral blood CD8+CD28+, CD8+CD28 T cell distribution and CD8+CD28+/CD8+CD28 T cells ratio between baseline and week 12, 24, 36, or 52.